$EXEL

Eckhardt Sue Gail sold $492K of EXEL

Eckhardt Sue Gail sold 9,812 shares of EXELIXIS, INC. (EXEL) at $50.14 ($0.49M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Eckhardt Sue Gail
Published Jun 3, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but the presence of a pre-arranged 10b5-1 plan reduces interpretability as a new bearish fundamental view.

02

Market read

A routine 10b5-1 insider sale; potential for minor short-term sentiment noise rather than a catalyst.

03

What to watch

Director sales can be driven by diversification/tax planning; without changes in buying activity or new company fundamentals, the signal is limited.

Relevance 6/10Novelty 4/10Timing: Filed after-hours on 2026-06-03; sale executed 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (director selling) for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

Director Eckhardt Sue Gail sold 9,812 EXELIXIS shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Mild, short-lived negative-to-neutral sentiment impact; unlikely to drive a sustained move by itself.

Evidence & confidence

The filing is a routine 10b5-1 sale by a director with no accompanying operational or financial catalyst described.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

If the market overweights insider selling, the 10b5-1 structure suggests the trade may be mechanical rather than a bearish signal.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale was reported on SEC Form 4.

  • Eckhardt Sue Gail

    Director who executed an open-market sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMed

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis (EXEL) announced a 3-month FDA review extension for zanzalintinib, now targeting March 3, 2027. The FDA requested updated safety and efficacy data. The drug, combined with atezolizumab, aims to treat metastatic colorectal cancer. Exelixis' approval prospects hinge on the full STELLAR-303 study data, which showed a statistically significant survival benefit in the overall population but not in a key subgroup.

$EXELMedAI 8/10

Does Extended FDA Review Change The Bull Case For Exelixis (EXEL)?

Exelixis (EXEL) announced a 3-month FDA review extension for its zanzalintinib plus atezolizumab NDA, moving the decision date to March 3, 2027. The delay is due to updated safety and efficacy data. Analysts highlight the impact on Exelixis' investment narrative, with near-term focus on the colorectal cancer decision. The company aims for $3.3B revenue and $1.3B earnings by 2029, with risks tied to CABOMETYX concentration and margin pressures.

$EXELMed

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis (EXEL) reported slower-than-expected revenue growth for CABOMETYX due to delayed treatment decisions in NET. The company maintains 47% new-patient market share and plans to launch zanza for colorectal cancer if approved. Exelixis expects CABOMETYX generics in 2031 and is investing in pipeline and share repurchases, with $600M remaining under its authorization.

$EXELLow

FDA Extends Review of Zanzalintinib Combo in Pretreated Metastatic CRC

The FDA extended its review of Exelixis' NDA for zanzalintinib plus atezolizumab to treat metastatic colorectal cancer, moving the PDUFA action date to March 3, 2027. The extension followed updated safety and efficacy data submission, classified as a major amendment. The NDA is supported by the STELLAR-303 trial, which showed a median OS of 10.9 months vs 9.4 months with regorafenib.